Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341113 | 0.82 | TDP1 (0.47) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL3087192 | 0.81 | LTA4H (0.45) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL29013847 | 0.81 | ELANE (0.43) | HPGDMAPTELANEALDH1A1BCHE | |
| SCHEMBL27575859 | 0.78 | TDP1 (0.44) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL707493 | 0.78 | PARP10 (0.44) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL6313194 | 0.77 | TDP1 (0.47) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL19247 | 0.77 | LTA4H (0.41) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL3302 | 0.77 | TDP1 (0.50) | TDP1ATML3MBTL1ALOX15HPGD | |
| Benzene SCHEMBL7925278 | 0.77 | TDP1 (0.50) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL370622 | 0.77 | TDP1 (0.50) | TDP1ATML3MBTL1ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | INNOVATIONAL HOLDINGS LLC | 2007-02-08 | — | — | US | claimed |
| EP-1562927-A2 | THIO-ANALOGUES OF PACLITAXEL AND INTERMEDIATES THEREOF | Phytogen Life Sciences Inc. (CA) | 2005-08-17 | — | — | EP | claimed |
| US-20040132991-A1 | Novel taxanes and methods related to use and preparation thereof | PHYTOGEN LIFE SCIENCES INC. (CA) | 2004-07-08 | — | — | US | claimed |
| WO-2004033442-A2 | NOVEL TAXANES AND METHODS RELATED TO USE AND PREPARATION THEREOF | CHATHAM BIOTEC LTD. (CA) | 2004-04-22 | — | — | WO | claimed |
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-8410095-B2 | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2004032871-A2 | PIPERAZINE AND PIPERAZINONE INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-0720605-B1 | AMINOCYCLOHEXYLESTERS AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2001-12-19 | — | — | EP | disclosed |
| US-6323212-B1 | METHOD FOR REDUCING PAIN, WHICH COMPRISES ADMINISTERING AN EFFECTIVE ANALGESIC AMOUNT OF THE MORPHINAN DERIVATIVE | TORAY INDUSTRIES, INC. (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-0577847-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-4343937-A | ANTIBIOTICS, BACTERICIDES | MERCK & CO., INC. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4342869-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4342757-A | Cephalosporin antibiotic compositions | MERCK & CO., INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4338437-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4338438-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4324890-A | ANTIBIOTICS, BACTERICIDES | MERCK & CO., INC. (US) | 1982-04-13 | — | — | US | disclosed |
| US-4297488-A | 7-α-Methoxy cephalosporins | MERCK & CO., INC. (US) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | TUBB8B, TUBA1B, TUBB | TDP1 193/4885ATM 1948/4885L3MBTL1 4636/4885 |
| US-20040132991-A1 | Novel taxanes and methods related to use and preparation thereof | TUBB8B, TUBA1B, TUBB | TDP1 193/4885ATM 1948/4885L3MBTL1 4636/4885 |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CA, PI4KA | TDP1 1563/4885ATM 482/4885L3MBTL1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.